Article Text

Download PDFPDF
Fas gene promoter –670 polymorphism in gynecological cancer
  1. M. Ueda,
  2. Y. Terai,
  3. K. Kanda,
  4. M. Kanemura,
  5. M. Takehara,
  6. H. Yamaguchi,
  7. K. Nishiyama,
  8. M. Yasuda and
  9. M. Ueki
  1. Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki Osaka, Japan
  1. Address correspondence and reprint requests to: Masatsugu Ueda, MD, Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. Email: gyn017{at}


Single-nucleotide polymorphism at −670 of Fas gene promoter (A/G) was examined in a total of 354 blood samples from normal healthy women and gynecological cancer patients. They consisted of 95 normal, 83 cervical, 108 endometrial, and 68 ovarian cancer cases. Eighty-three patients with cervical cancer had statistically higher frequency of GG genotype and G allele than 95 controls (P= 0.0353 and 0.0278, respectively). There was no significant difference in the genotype or allele prevalence between control subjects and endometrial or ovarian cancer patients. The Fas −670 GG genotype was associated with an increased risk for the development of cervical cancer (OR = 2.56, 95% CI = 1.08–6.10) compared with the AA genotype. The G allele also increased the risk of cervical cancer (OR = 1.60, 95% CI = 1.05–2.43) compared with the A allele. Germ-line polymorphism of Fas gene promoter −670 may be associated with the risk of cervical cancer in a Japanese population.

  • gynecological cancer
  • Fas
  • polymorphism

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.